-
公开(公告)号：US09632091B2
公开(公告)日：2017-04-25
申请号：US14919388
申请日：2015-10-21
Applicant: Genentech, Inc.
Inventor： Siminder Atwal , Jo-Anne Hongo , Mark Lackner , Elizabeth Punnoose , Bonnee Rubinfeld , Rajesh Vij
IPC: G01N33/53 , G01N33/574 , C07K16/30 , C12N5/09
CPC classification number: G01N33/57434 , C07K16/3069 , C12N5/0693 , C12Y116/01 , C12Y301/03048 , G01N33/57492 , G01N2333/4742 , G01N2333/70596 , G01N2333/90287 , G01N2333/916 , G01N2800/52
Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
-
公开(公告)号：US20170065588A1
公开(公告)日：2017-03-09
申请号：US15237412
申请日：2016-08-15
Applicant: Genentech, Inc.
Inventor： Kui Lin , Elizabeth Punnoose , Somasekar Seshagiri
IPC: A61K31/517 , C12Q1/68 , A61K31/58 , G01N33/574
CPC classification number: A61K31/517 , A61K31/58 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/5748
Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.
Abstract translation: 本文提供了用于预测对癌症治疗的敏感性的生物标志物和生物标志物的组合。
-
3.发明申请COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE 审中-公开AKT抑制剂化合物和化学治疗剂的组合及使用方法公开(公告)号：US20160228440A1
公开(公告)日：2016-08-11
申请号：US15017315
申请日：2016-02-05
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/517 , A61K31/4166
CPC classification number: A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
Abstract translation: 本发明提供组合，其包含a）式I化合物或其药学上可接受的盐，其中R 1，R 2，R 5，R 10和A具有说明书中定义的任何值; 和b）选自5-FU，铂药剂，甲酰四氢叶酸，伊立替康，多西他赛，多柔比星，吉西他滨，SN-38，卡培他滨，替莫唑胺，紫杉醇，贝伐珠单抗，依托单抗，他莫昔芬，雷帕霉素和拉帕替尼的一种或多种药剂。 这些组合对于治疗过度增殖性疾病如癌症特别有用。
-
公开(公告)号：US20130143237A1
公开(公告)日：2013-06-06
申请号：US13689407
申请日：2012-11-29
Applicant: Genentech, Inc.
Inventor： Siminder Atwal , Jo-Anne Hongo , Mark Lackner , Elizabeth Punnoose , Bonnee Rubinfeld , Rajesh Vij
CPC classification number: G01N33/57434 , C07K16/3069 , C12N5/0693 , C12Y116/01 , C12Y301/03048 , G01N33/57492 , G01N2333/4742 , G01N2333/70596 , G01N2333/90287 , G01N2333/916 , G01N2800/52
Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
Abstract translation: 本发明提供诊断前列腺癌的方法。 本发明还提供新的抗STEAP-1抗体及其用途。
-
Patent Agency Ranking
公开(公告)号：US10092567B2
公开(公告)日：2018-10-09
申请号：US15438277
申请日：2017-02-21
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/00 , A61K31/4745 , A61K31/495 , C07D239/70 , A61K31/517 , A61K31/437 , A61K31/496 , A61K31/58 , A61K31/282 , A61K31/337 , A61K31/4188 , A61K31/513 , A61K31/519 , A61K31/704 , A61K39/395 , C07D403/12 , A61K31/436 , A61K31/138 , A61K31/4166 , A61K31/555 , A61K31/7068 , C07K16/40 , A61K39/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
-
公开(公告)号：US09717730B2
公开(公告)日：2017-08-01
申请号：US15017315
申请日：2016-02-05
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/00 , A61K31/4745 , A61K31/495 , C07D239/70 , A61K31/517 , A61K31/437 , A61K31/496 , A61K31/58 , A61K31/282 , A61K31/337 , A61K31/4188 , A61K31/513 , A61K31/519 , A61K31/704 , A61K39/395 , C07D403/12 , A61K31/436 , A61K31/138 , A61K31/4166 , A61K31/555 , A61K31/7068 , C07K16/40 , A61K39/00
CPC classification number: A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
-
7.发明申请PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY 审中-公开PI3K / AKT激酶生物标志物生物标志物对路线抑制剂的有效性公开(公告)号：US20130059859A1
公开(公告)日：2013-03-07
申请号：US13653292
申请日：2012-10-16
Applicant: Genentech, Inc.
Inventor： Elizabeth Punnoose
IPC: A61K31/496 , A61P35/00 , C12Q1/68 , G01N33/566 , G01N33/573
CPC classification number: G01N33/57496 , G01N2333/4701 , G01N2333/912 , G01N2800/52
Abstract: A method of predicting the sensitivity of tumor cell growth to inhibition by a PI3K/AKT kinase pathway inhibitor, comprising: determining the localization profile of FOXO3a in a tumor cell, wherein a cytoplasmic localization profile of FOXO3a correlates with sensitivity to inhibition by a PI3K/AKT kinase inhibitor and a nuclear localization profile of FOXO3a correlates with resistance to inhibition by a PI3K/AKT kinase inhibitor.
Abstract translation: 一种预测肿瘤细胞生长对PI3K / AKT激酶途径抑制剂抑制的敏感性的方法，包括：确定FOXO3a在肿瘤细胞中的定位分布，其中FOXO3a的细胞质定位分布与PI3K / AKT激酶抑制剂和FOXO3a的核定位分布与PI3K / AKT激酶抑制剂对抑制的抗性有关。
-
公开(公告)号：US20180360835A1
公开(公告)日：2018-12-20
申请号：US16122713
申请日：2018-09-05
Applicant: Genentech, Inc.
Inventor： Kui Lin , Elizabeth Punnoose , Somasekar Seshagiri
IPC: A61K31/517 , A61K31/58 , G01N33/574 , C12Q1/6886
Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.
-
9.发明申请公开(公告)号：US20170157124A1
公开(公告)日：2017-06-08
申请号：US15438277
申请日：2017-02-21
Applicant: Genentech, Inc.
Inventor： Kui Lin , Michelle Nannini , Elizabeth Punnoose , Deepak Sampath , Jeffrey Wallin , Premal Patel
IPC: A61K31/517 , A61K31/337
CPC classification number: A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.022 seconds)
